Macquarie Group
IONS icon

Macquarie Group’s Ionis Pharmaceuticals IONS Stock Holding History

Macquarie Group’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,131,936
Closed -$74.1M – 1165
2025
Q3 		$74.1M Sell
1,131,936
-302,137
-21% -$14.8M 0.09% 311
2025
Q2 		$56.7M Sell
1,434,073
-233,121
-14% -$7.63M 0.07% 386
2025
Q1 		$50.3M Sell
1,667,194
-102,549
-6% -$3.36M 0.06% 404
2024
Q4 		$61.9M Sell
1,769,743
-100,063
-5% -$3.74M 0.08% 360
2024
Q3 		$74.9M Sell
1,869,806
-3,862
-0.2% -$180K 0.08% 334
2024
Q2 		$89.3M Sell
1,873,668
-1,326,910
-41% -$54.4M 0.1% 256
2024
Q1 		$139M Buy
3,200,578
+112,343
+4% +$5.35M 0.16% 167
2023
Q4 		$156M Buy
3,088,235
+152,311
+5% +$7.3M 0.18% 144
2023
Q3 		$133M Buy
2,935,924
+1,437,042
+96% +$59.3M 0.17% 160
2023
Q2 		$61.5M Buy
1,498,882
+4,979
+0.3% +$191K 0.07% 360
2023
Q1 		$53.4M Buy
1,493,903
+2,216
+0.1% +$83.2K 0.06% 399
2022
Q4 		$56.3M Buy
1,491,687
+657,646
+79% +$27.7M 0.07% 403
2022
Q3 		$37M Buy
834,041
+800,773
+2,407% +$33.7M 0.05% 519
2022
Q2 		$1.23M Buy
33,268
+1,262
+4% +$47.6K ﹤0.01% 1435
2022
Q1 		$1.19K Sell
32,006
-543
-2% -$17.8K ﹤0.01% 1512
2021
Q4 		$991K Buy
32,549
+121
+0.4% +$3.81K ﹤0.01% 1557
2021
Q3 		$1.09M Hold
32,428
– – ﹤0.01% 1567
2021
Q2 		$1.29M Buy
32,428
+1,971
+6% +$77.2K ﹤0.01% 1545
2021
Q1 		$1.37M Buy
30,457
+6,344
+26% +$354K ﹤0.01% 1316
2020
Q4 		$1.36M Buy
24,113
+348
+1% +$17.3K ﹤0.01% 1222
2020
Q3 		$1.13M Sell
23,765
-221
-0.9% -$12.3K ﹤0.01% 1211
2020
Q2 		$1.41M Sell
23,986
-6,616
-22% -$368K ﹤0.01% 1118
2020
Q1 		$1.45M Buy
30,602
+2,539
+9% +$142K ﹤0.01% 999
2019
Q4 		$1.7M Buy
28,063
+7,440
+36% +$443K ﹤0.01% 1086
2019
Q3 		$1.24M Buy
20,623
+2,606
+14% +$170K ﹤0.01% 1156
2019
Q2 		$1.16M Buy
18,017
+491
+3% +$34.7K ﹤0.01% 1180
2019
Q1 		$1.42M Sell
17,526
-6,463
-27% -$417K ﹤0.01% 1087
2018
Q4 		$1.3M Buy
23,989
+623
+3% +$31.8K ﹤0.01% 1079
2018
Q3 		$1.21M Sell
23,366
-6,377
-21% -$300K ﹤0.01% 1161
2018
Q2 		$1.24M Buy
+29,743
New +$1.32M ﹤0.01% 1127
2016
Q2 		– Sell
-1,842
Closed -$75K – 1608
2016
Q1 		$75K Hold
1,842
– – ﹤0.01% 1455
2015
Q4 		$114K Buy
1,842
+101
+6% +$5.45K ﹤0.01% 1403
2015
Q3 		$70K Sell
1,741
-43,343
-96% -$2.24M ﹤0.01% 1513
2015
Q2 		$2.6M Sell
45,084
-139,997
-76% -$8.9M 0.01% 958
2015
Q1 		$11.8M Buy
185,081
+59,666
+48% +$4.05M 0.02% 505
2014
Q4 		$7.74M Buy
125,415
+38,849
+45% +$1.92M 0.02% 589
2014
Q3 		$3.36M Buy
+86,566
New +$3.07M 0.01% 831

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Macquarie Group's IONS Position: Q4 2025 in Review

Macquarie Group sold out of Ionis Pharmaceuticals (IONS) in Q4 2025, closing a stake of 1,131,936 shares — an estimated $74.1M sold.

Macquarie Group first reported a position in IONS in Q3 2014 and held it in 37 quarters. The position peaked at $156M in Q4 2023. 491 funds tracked by Wall St. Rank hold IONS as of Q4 2025.

  • Macquarie Group reported no remaining Ionis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Macquarie Group sold 1,131,936 Ionis Pharmaceuticals shares in Q4 2025, an estimated $74.1M.
  • Macquarie Group first reported a position in Ionis Pharmaceuticals in Q3 2014 and held it in 37 quarters.
  • Macquarie Group's Ionis Pharmaceuticals position peaked at $156M in Q4 2023.
  • 491 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2025.

Based on Macquarie Group's 13F filing for Q4 2025, filed 13 Feb 2026.